Japan approves Moderna COVID-19 vaccine

By The Science Advisory Board staff writers

May 21, 2021 -- Japan's Ministry of Health, Labour, and Welfare recently approved Moderna's COVID-19 vaccine, and distribution in the country by Takeda will begin immediately.

The approval is based on Moderna's phase III Coronavirus Efficacy (COVE) study results and positive initial clinical data from the Takeda-led placebo-controlled phase III study.

Takeda and Moderna previously announced that Takeda will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021. The companies have affirmed discussions reported recently for an additional potential supply of 50 million doses from the beginning of 2022.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.